ArticleCancer research communications2026
Characterization of Mitochondrial Double-Stranded RNA Levels in Non-Small Cell Lung Carcinoma.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Mitochondrial double-stranded RNA (mtdsRNA) is exported to the cytoplasm when mitochondrial RNA degradation is impaired, serving as a novel damage-associated molecular pattern for mitochondrial stress. Although mtdsRNA has been detected in certain cancers, its prevalence and functional role remain largely underexplored. Moreover, mtdsRNA is not readily detectable in large-scale computational datasets, reflecting technical limitations in the detection of structured mitochondrial transcripts. In this study, we used comprehensive computational characterization of non-small cell lung cancer (NSCLC) cell lines and identified elevated light-strand transcripts in a subset of cell lines, suggesting a potential for mtdsRNA formation. We stratify NSCLC lines into groups with high and low mtdsRNA abundance. Despite high cytoplasmic mtdsRNA levels in select NSCLC cell lines, we did not identify significant correlation with mtdsRNA abundance and type-I interferon (IFN-l) response. RT-qPCR analysis revealed that only USP18 transcripts amongst the IFN-l transcripts probed were significantly regulated in select NSCLC lines, indicating a partial or suppressed IFN-I response. Strand-specific RT-qPCR also revealed no bias in mitochondrial gene expression. These findings indicate that basal mtdsRNA accumulation alone is insufficient to trigger IFN-I signaling and may be tolerated in NSCLC, indicating adaptive mechanisms. Our findings suggest that mtdsRNAs could serve alternative nonimmunogenic roles in tumor biology. Importantly, our work reports that mtdsRNA is upregulated in a subset of NSCLC cell lines and in other cancer cell types, suggesting that mtdsRNA may serve as a new marker of mitochondrial dysfunction in cancer. SIGNIFICANCE: Our study identified and characterized NSCLC cell lines with elevated mtdsRNAs, suggesting that mtdsRNA may be a new signaling molecule in lung cancer for mitochondrial stress. We identified that accumulation of mtdsRNAs did not necessarily activate IFN-l response, indicating that NSCLC cell lines may have adaptive mechanisms to reduce IFN-l response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.